000			01491 a2200385 4500
005			20250513081051.0
264		0	_c19930427
008			199304s 0 0 eng d
022			_a0074-7718
024	7		_a10.1016/b978-0-12-364935-5.50020-1 _2doi
040			_aNLM _beng _cNLM
100	1		_aStern, A C
245	0	0	_aClinical experience with Escherichia coli rHuGM-CSF. _h[electronic resource]
260			_bInternational review of experimental pathology _c1993
300			_a209-16 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAntiviral Agents _xadverse effects
650	0	4	_aBone Marrow Transplantation
650	0	4	_aClinical Trials as Topic
650	0	4	_aEscherichia coli _xgenetics
650	0	4	_aGraft Survival _xdrug effects
650	0	4	_aGranulocyte-Macrophage Colony-Stimulating Factor _xadverse effects
650	0	4	_aHumans
650	0	4	_aImmunologic Factors _xadverse effects
650	0	4	_aInflammation _xchemically induced
650	0	4	_aMyelodysplastic Syndromes _xtherapy
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aPostoperative Care
650	0	4	_aRecombinant Fusion Proteins _xadverse effects
650	0	4	_aTreatment Outcome
700	1		_aJones, T C
773	0		_tInternational review of experimental pathology _gvol. 34 Pt B _gp. 209-16
856	4	0	_uhttps://doi.org/10.1016/b978-0-12-364935-5.50020-1 _zAvailable from publisher's website
999			_c8457985 _d8457985